SCHAUMBURG, Ill.--(BUSINESS WIRE)--Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Letrozole Tablets in the U.S., after the U.S.

Novartis Oncology announces that the U.S. Food and Drug Administration has approved Femara(R) (letrozole tablets) for the first-line treatment of postmenopausal women with hormone receptor positive or ...

Please provide your email address to receive an email when new articles are posted on . Results from a phase 2 study showed that abemaciclib in combination with letrozole shrunk or stabilized tumors ...

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall ...

Postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer: The ENGOT-EN2/DGCG trial. Background: Endometrial cancer (EC ...

In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with ...